Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie dotyczące jednoczesnego podawania szczepionki zawierającej żywy, atenuowany wirus syncytialny układu oddechowego u niemowląt i małych dzieci (CORAL)

15 września 2026 zaktualizowane przez: Sanofi Pasteur, a Sanofi Company

Faza III, randomizowane, wieloośrodkowe badanie z pojedynczą ślepą próbą, kontrolowane placebo, mające na celu ocenę braku wpływu jednoczesnego podawania rutynowych szczepionek pediatrycznych na odpowiedź przeciwciał badanej szczepionki z żywym atenuowanym wirusem Syncytialnego układu oddechowego (RSV) u zdrowych niemowląt i dzieci Małe dzieci (KORAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

Przegląd badań

Status

Zakończony

Warunki

Interwencja / Leczenie

Szczegółowy opis

The study duration is approximately 9 months for each participant.

  • Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
  • Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
  • Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

2226

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Mexico City, Meksyk, 06760
        • Investigational Site Number : 4840004
    • Mexico City
      • Mexico City, Mexico City, Meksyk, 04530
        • Investigational Site Number : 4840001
    • Morelos
      • Temixco, Morelos, Meksyk, 62587
        • Investigational Site Number : 4840002
      • Caguas, Portoryko, 00725
        • Investigational Site Number : 6300001
      • Ponce, Portoryko, 00716
        • Investigational Site Number : 6300003
      • Trujillo Alto, Portoryko, 00976
        • Investigational Site Number : 6300004
    • Alabama
      • Birmingham, Alabama, Stany Zjednoczone, 35205
        • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
      • Grand Bay, Alabama, Stany Zjednoczone, 36541
        • South Alabama Medical Clinic- Site Number : 8400065
      • Mobile, Alabama, Stany Zjednoczone, 36608
        • MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
    • Arkansas
      • Fayetteville, Arkansas, Stany Zjednoczone, 72703
        • Northwest Arkansas Pediatric Clinic- Site Number : 8400002
    • California
      • Bell Gardens, California, Stany Zjednoczone, 90201
        • Alliance Research Institute - Bell Gardens - Garfield Avenue- Site Number : 8400040
      • Huntington Park, California, Stany Zjednoczone, 90255
        • Matrix Clinical Research - Huntington Park- Site Number : 8400018
      • La Mesa, California, Stany Zjednoczone, 91942
        • Paradigm Clinical Research Centers- Site Number : 8400059
      • Los Angeles, California, Stany Zjednoczone, 90057
        • Matrix Clinical Research - Los Angeles- Site Number : 8400008
      • Oakland, California, Stany Zjednoczone, 94611
        • Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
      • Palo Alto, California, Stany Zjednoczone, 94304
        • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400070
      • Roseville, California, Stany Zjednoczone, 95661
        • Kaiser Permanente - Sierra Gardens- Site Number : 8400063
      • Sacramento, California, Stany Zjednoczone, 95815
        • Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
      • San Jose, California, Stany Zjednoczone, 95119
        • Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
      • Santa Clara, California, Stany Zjednoczone, 95051
        • Kaiser Permanente - Santa Clara Medical Center- Site Number : 8400061
      • Sherman Oaks, California, Stany Zjednoczone, 91356-4173
        • Integrated Clinical Research LLC- Site Number : 8400036
      • Walnut Creek, California, Stany Zjednoczone, 94596
        • Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
    • District of Columbia
      • Washington D.C., District of Columbia, Stany Zjednoczone, 20016
        • Velocity Clinical Research - Washington DC- Site Number : 8400050
    • Florida
      • Doral, Florida, Stany Zjednoczone, 33166
        • Prohealth Research Center- Site Number : 8400068
      • Hollywood, Florida, Stany Zjednoczone, 33021
        • The Medici Medical Research- Site Number : 8400055
      • Miami, Florida, Stany Zjednoczone, 33126
        • Dade Research Center- Site Number : 8400014
      • Miami Lakes, Florida, Stany Zjednoczone, 33014
        • Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400015
      • Pensacola, Florida, Stany Zjednoczone, 32501
        • SEC Clinical Research - Pensacola- Site Number : 8400034
      • Tampa, Florida, Stany Zjednoczone, 33613
        • PAS Research- Site Number : 8400005
    • Idaho
      • Idaho Falls, Idaho, Stany Zjednoczone, 83404
        • Leavitt Women's Healthcare- Site Number : 8400009
    • Iowa
      • Sioux City, Iowa, Stany Zjednoczone, 51106
        • Velocity Clinical Research - Sioux City- Site Number : 8400054
    • Kansas
      • El Dorado, Kansas, Stany Zjednoczone, 67042
        • Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
    • Kentucky
      • Lexington, Kentucky, Stany Zjednoczone, 40536
        • University of Kentucky Chandler Medical Center- Site Number : 8400051
    • Louisiana
      • New Orleans, Louisiana, Stany Zjednoczone, 70119
        • Velocity Clinical Research - New Orleans- Site Number : 8400058
      • New Orleans, Louisiana, Stany Zjednoczone, 70125
        • Research Works INC- Site Number : 8400044
    • Mississippi
      • Gulfport, Mississippi, Stany Zjednoczone, 39503
        • Velocity Clinical Research - Gulfport- Site Number : 8400011
    • Missouri
      • Springfield, Missouri, Stany Zjednoczone, 65802
        • QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
    • Montana
      • Great Falls, Montana, Stany Zjednoczone, 59405
        • Boeson Research - Great Falls- Site Number : 8400041
      • Missoula, Montana, Stany Zjednoczone, 59804
        • Boeson Research - Missoula- Site Number : 8400006
    • Nebraska
      • Grand Island, Nebraska, Stany Zjednoczone, 68803
        • Velocity Clinical Research - Grand Island- Site Number : 8400016
      • Lincoln, Nebraska, Stany Zjednoczone, 68516
        • Midwest Childrens Health Research Institute- Site Number : 8400038
      • Omaha, Nebraska, Stany Zjednoczone, 68134
        • Velocity Clinical Research - Omaha- Site Number : 8400001
    • Nevada
      • Henderson, Nevada, Stany Zjednoczone, 89014
        • PAS Research - Henderson- Site Number : 8400049
    • New York
      • Garden City, New York, Stany Zjednoczone, 11530
        • NYU Langone Cardiothoracic Surgery Associates - Garden City- Site Number : 8400048
      • Liverpool, New York, Stany Zjednoczone, 13088
        • Summerwood Pediatrics- Site Number : 8400021
      • Syracuse, New York, Stany Zjednoczone, 13210
        • SUNY Upstate Medical University - Syracuse- Site Number : 8400029
    • Ohio
      • Dayton, Ohio, Stany Zjednoczone, 45414
        • Ohio Pediatrics - Dayton- Site Number : 8400033
      • Dayton, Ohio, Stany Zjednoczone, 45409
        • Dayton Clinical Research- Site Number : 8400030
      • South Euclid, Ohio, Stany Zjednoczone, 44121
        • Senders Pediatrics- Site Number : 8400022
    • Oregon
      • Gresham, Oregon, Stany Zjednoczone, 97030
        • Cyn3rgy Research- Site Number : 8400053
    • Pennsylvania
      • Erie, Pennsylvania, Stany Zjednoczone, 16506
        • Square-1 Clinical Research- Site Number : 8400031
      • Pittsburgh, Pennsylvania, Stany Zjednoczone, 15227
        • Pas Research - Pittsburgh- Site Number : 8400043
    • South Carolina
      • Charleston, South Carolina, Stany Zjednoczone, 29407
        • Neighbors Pediatrics- Site Number : 8400072
      • Greenville, South Carolina, Stany Zjednoczone, 29607
        • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400012
    • Texas
      • Corpus Christi, Texas, Stany Zjednoczone, 78413
        • South Texas Clinical Research- Site Number : 8400004
      • Dallas, Texas, Stany Zjednoczone, 75230
        • Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
      • Edinburg, Texas, Stany Zjednoczone, 78539
        • PAS Research - Children's Care Clinic- Site Number : 8400035
      • Fort Worth, Texas, Stany Zjednoczone, 76104
        • Helios Clinical Research - Fort Worth - 8th Avenue- Site Number : 8400020
      • Houston, Texas, Stany Zjednoczone, 77008
        • Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
      • Houston, Texas, Stany Zjednoczone, 77065
        • DM Clinical Research - Houston - Jones Road- Site Number : 8400052
      • Houston, Texas, Stany Zjednoczone, 77070
        • Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
      • Houston, Texas, Stany Zjednoczone, 77090
        • Houston Clinical Research Associates- Site Number : 8400013
      • Houston, Texas, Stany Zjednoczone, 77030
        • The University of Texas Health Science Center- Site Number : 8400037
      • Houston, Texas, Stany Zjednoczone, 77071
        • La Providence Pediatrics & Family Clinics- Site Number : 8400039
      • League City, Texas, Stany Zjednoczone, 77555
        • University of Texas Medical Branch at Galveston- Site Number : 8400057
      • League City, Texas, Stany Zjednoczone, 77573
        • Maximos Ob/Gyn- Site Number : 8400024
      • Plano, Texas, Stany Zjednoczone, 75093
        • Research Your Health- Site Number : 8400066
      • Richmond, Texas, Stany Zjednoczone, 77469
        • Pediatric Center - Richmond- Site Number : 8400032
      • Tomball, Texas, Stany Zjednoczone, 77375
        • North Houston Internal Medicine & Pediatric Clinic- Site Number : 8400025
    • Utah
      • Orem, Utah, Stany Zjednoczone, 84057
        • Utah Valley Pediatrics - Orem- Site Number : 8400067
      • Pleasant View, Utah, Stany Zjednoczone, 84404
        • Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
      • Roy, Utah, Stany Zjednoczone, 84067
        • Wee Care Pediatrics - Roy- Site Number : 8400071

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

6 miesięcy do 1 rok (Dziecko)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
  • Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:
  • A person living with human immunodeficiency virus (HIV)
  • A person who has received chemotherapy within the 12 months prior to study enrollment
  • A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • A person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol
  • Participant's biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding
  • Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
  • Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
  • For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
  • For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Zapobieganie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Potroić

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Inne nazwy:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • RECOMBIVAX HB® lub alternatywna monowalentna szczepionka przeciw wirusowemu zapaleniu wątroby typu B

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Inne nazwy:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Eksperymentalny: Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Inne nazwy:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • RECOMBIVAX HB® lub alternatywna monowalentna szczepionka przeciw wirusowemu zapaleniu wątroby typu B

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Inne nazwy:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Eksperymentalny: Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Inne nazwy:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Inne nazwy:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Inne nazwy:
  • VARIVAX®
Eksperymentalny: Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Inne nazwy:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Inne nazwy:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Inne nazwy:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Inne nazwy:
  • VARIVAX®

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Ramy czasowe: Day 85

Antibody titers at Day 85

Day 85
RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Ramy czasowe: Day 85

Antibody titers at Day 85

Day 85
RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4
Ramy czasowe: Day 113

Antibody titers at Day 113

Day 113
RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4
Ramy czasowe: Day 113

Antibody titers at Day 113

Day 113

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by ECL Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1
Ramy czasowe: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)
Ramy czasowe: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Ramy czasowe: Day 1

Antibody titers at Day 1

Day 1
RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Ramy czasowe: Day 1

Antibody titers at Day 1

Day 1
RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2
Ramy czasowe: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2
Ramy czasowe: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2
Ramy czasowe: 21 days after each IMP administration

Number of participants experiencing solicited administration site reactions

21 days after each IMP administration
Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2
Ramy czasowe: 21 days after each IMP administration

Number of participants experiencing solicited systemic site reactions

21 days after each IMP administration
Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2
Ramy czasowe: Within 30 minutes after each study intervention administration

Number of participants experiencing unsolicited systemic adverse events

Within 30 minutes after each study intervention administration
Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2
Ramy czasowe: Within 28 days after each study intervention administration

Number of participants experiencing unsolicited AEs

Within 28 days after each study intervention administration
Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2
Ramy czasowe: Throughout the study, approximately 9 months

Number of participants experiencing MAAEs

Throughout the study, approximately 9 months
Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2
Ramy czasowe: Throughout the study, approximately 9 months

Number of participants experiencing SAEs

Throughout the study, approximately 9 months
Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2
Ramy czasowe: Throughout the study, approximately 9 months

Number of participants experiencing AESIs

Throughout the study, approximately 9 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

13 maja 2024

Zakończenie podstawowe (Rzeczywisty)

18 września 2025

Ukończenie studiów (Rzeczywisty)

18 września 2025

Daty rejestracji na studia

Pierwszy przesłany

29 kwietnia 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

29 kwietnia 2024

Pierwszy wysłany (Rzeczywisty)

3 maja 2024

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

5 października 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

15 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • VAD00016
  • VAD00016 (Inny identyfikator: Sanofi Identifier)
  • U1111-1290-7356 (Identyfikator rejestru: ICTRP)
  • 2024-000262-15 (Numer EudraCT)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .